Literature DB >> 28096524

A Case of Seronegative Limbic Encephalitis with Multiple Sclerosis: A Possible Overlapping Syndrome.

Zerrin Karaaslan1, Özlem Mercan2, Erdem Tüzün1, Handan Mısırlı2, Recai Türkoğlu2.   

Abstract

BACKGROUND Autoimmune encephalitis might coexist in patients with autoimmune demyelinating disorders. CASE REPORT We report on a case of a 45-year-old female multiple sclerosis (MS) patient presenting with acute onset short-term memory loss, altered mental status, inflammatory cerebrospinal fluid (CSF) findings and an MRI lesion on the left temporal lobe. An extensive panel for neuronal autoantibodies proved negative. Neuropsychological symptoms gave a prompt response to immunotherapy but nevertheless control MRI showed left hippocampal atrophy. CONCLUSIONS Several recent reports of concurrent emergence of autoimmune encephalitis and MS suggest a common mechanism for these disorders. Since autoimmune encephalitis and MS share certain common CSF and neuroimaging findings, an increased understanding of overlapping autoimmune brain disorders is required to avoid misdiagnosis especially in antibody negative autoimmune encephalitis cases.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28096524      PMCID: PMC5266202          DOI: 10.12659/ajcr.901391

Source DB:  PubMed          Journal:  Am J Case Rep        ISSN: 1941-5923


Background

Multiple sclerosis (MS) is a demyelinating autoimmune disorder of the central nervous system and might coexist with other autoimmune diseases such as type 1 diabetes mellitus, inflammatory bowel disease, and autoimmune thyroiditis [1]. Previously reported cases of anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis co-occurring with neuromyelitis optica, optic neuritis, and MS have led to the emergence of the so-called “overlapping syndrome” [2-4]. A recent study found neuroimaging features suggesting a demyelinating disorder in approximately 3% of NMDAR encephalitis patients [3]. Moreover, NMDAR encephalitis occasionally presents with immunotherapy responsive white matter lesions [5]. However, to our knowledge, concurrent emergence of demyelinating disorders with other types of autoimmune encephalitis has not been reported.

Case Report

A 45-year-old woman (height 165 cm, weight 72 kg), diagnosed four years ago with MS according to McDonald’s criteria [6] due to three separate inflammatory demyelinating episodes (optic neuritis, diplopia, and left hemiparesis) with contrast-enhancing MS lesions (brainstem and periventricular white matter) on magnetic resonance imaging (MRI), was admitted with a 15-day history of anhedonia, involuntary crying episodes, short-term memory impairment, and time/place disorientation. She was under interferon beta-1b treatment during admission and she had no history of other neurological or psychiatric diseases. Her somatic neurological examination was normal. MRI studies showed left medial temporal hyperintensity and multiple ovoid lesions in the white matter with no gadolinium enhancement (Figure 1A, 1B). EEG revealed slow waves over the left hemisphere. Cerebrospinal fluid (CSF) analysis showed increased number of lymphocytes (17/mm3), elevated protein level (62 mg/dL) and oligoclonal bands (in CSF only, pattern 2). CSF PCR assays for viral pathogens (VZV, HSV1/2, CMV, and HHV-6) and an extensive panel for rheumatological-vasculitic disorders were negative. Serum and CSF samples were negative for antibodies against Hu, Ri, Ma2, CV2, amphiphysin, NMDAR, α-amino-hydroxy-methyl-isoxazolepropionic acid (AMPA) receptor, contactin-associated protein-like 2 (CASPR2), leucine-rich, glioma inactivated 1 (LGI1), gamma-amino butyric acid (GABA)B receptor, glutamic acid decarboxylase (GAD), aquaporin-4, and myelin oligodendrocyte glyco-protein. A whole body positron emission tomography (PET) scan done for a potential underlying tumor proved negative. Seronegative limbic encephalitis was considered on the basis of clinical, neuroimaging, and CSF findings. Her symptoms ceased two weeks after monthly treatments of intravenous methylprednisolone (1000 mg/day) and intravenous immunoglobulin (0.4 g/kg/day). A control cranial MRI showed normal signal intensity and atrophy in the left temporal lobe (Figure 1C). The patient was discharged three months later without neurological symptoms.
Figure 1.

Axial FLAIR: (A) and coronal T2-weighted (B) images show increased abnormal signal intensity in the left hippocampalparahippocampal area (arrows) as well as multiple periventricular-deep white matter demyelinating lesions. Coronal postcontrast T1-weighted image (C) shows atrophy in the left medial temporal region (arrow) two weeks after the symptom onset.

Discussion

Although our patient had the typical clinical features and MRI lesions of MS, her neuropsychiatric manifestations and left temporal lobe involvement were atypical for MS. Moreover, her clinical features and EEG-CSF findings fulfilled the recently published criteria for seronegative autoimmune encephalitis (rapid progression of short-term memory deficit, and altered mental status, temporal lobe lesion on MRI, inflammatory CSF findings, exclusion of alternative causes) [7], thus prompting the diagnosis of limbic encephalitis overlapping with MS. Prompt response to immunotherapy and residual hippocampal atrophy occasionally seen in autoimmune encephalitis [8] further supported this diagnosis. Concurrent emergence of MS and autoimmune encephalitis might be discussed through different perspectives. Oligodendrocytes express NMDAR and other ion channels and thus antibodies involved in autoimmune encephalitis pathogenesis might also participate in myelin dysfunction [9]. Although our patient was negative for an extensive panel of anti-neuronal antibodies, she might hypothetically have developed as yet uncharacterized antibodies leading to both an MS-like disease and limbic encephalitis. Alternatively, the activated auto-immune system and disrupted blood-brain barrier in MS patients might facilitate emergence of other autoimmune brain disorders. Also, overlapping syndrome patients might have an immunogenetic background rendering them susceptible to diverse autoimmune brain diseases. Higher levels of acute-phase proteins, such as ceruloplasmin, have been shown to occur in MS patients treated with interferon-beta [10]. Thus, immunomodulatory treatment might plausibly activate inflammation pathways and induce susceptibility to autoimmune encephalitis-related processes in the brain.

Conclusions

Our case emphasizes that concurrent autoimmune encephalitis and MS may occur in seronegative patients and the spectrum of overlapping syndrome is presumably wider than previously considered. MS and autoimmune encephalitis share similar CSF findings such as oligoclonal bands, and autoimmune encephalitis patients may frequently present with white matter lesions posing a significant diagnostic challenge especially in seronegative cases. Therefore, awareness of overlapping syndrome is important in differential diagnosis of neuroimmunological disorders of the brain.
  10 in total

1.  Anti-N-methyl D-aspartate-type glutamate receptor antibody-positive limbic encephalitis in a patient with multiple sclerosis.

Authors:  Akiyuki Uzawa; Masahiro Mori; Yukitoshi Takahashi; Yoshitsugu Ogawa; Tomoyuki Uchiyama; Satoshi Kuwabara
Journal:  Clin Neurol Neurosurg       Date:  2011-12-05       Impact factor: 1.876

2.  Autoimmune Comorbidities Are Associated with Brain Injury in Multiple Sclerosis.

Authors:  R Zivadinov; B Raj; M Ramanathan; B Teter; J Durfee; M G Dwyer; N Bergsland; C Kolb; D Hojnacki; R H Benedict; B Weinstock-Guttman
Journal:  AJNR Am J Neuroradiol       Date:  2016-02-18       Impact factor: 3.825

3.  [Anti-NMDA receptor antibody encephalitis with recurrent optic neuritis and epilepsy].

Authors:  Rie Motoyama; Kazuhiro Shiraishi; Keiko Tanaka; Masako Kinoshita; Masami Tanaka
Journal:  Rinsho Shinkeigaku       Date:  2010-08

4.  Outcome of limbic encephalitis with VGKC-complex antibodies: relation to antigenic specificity.

Authors:  M P Malter; C Frisch; J C Schoene-Bake; C Helmstaedter; K P Wandinger; W Stoecker; H Urbach; R Surges; C E Elger; A V Vincent; C G Bien
Journal:  J Neurol       Date:  2014-06-17       Impact factor: 4.849

5.  Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.

Authors:  Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2011-02       Impact factor: 10.422

Review 6.  Neuroimmunology: an expanding frontier in autoimmunity.

Authors:  Romana Höftberger
Journal:  Front Immunol       Date:  2015-04-29       Impact factor: 7.561

7.  NMDA receptor antibodies associated with distinct white matter syndromes.

Authors:  Yael Hacohen; Michael Absoud; Cheryl Hemingway; Leslie Jacobson; Jean-Pierre Lin; Mike Pike; Sunil Pullaperuma; Ata Siddiqui; Evangeline Wassmer; Patrick Waters; Sarosh R Irani; Camilla Buckley; Angela Vincent; Ming Lim
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2014-04-24

Review 8.  A clinical approach to diagnosis of autoimmune encephalitis.

Authors:  Francesc Graus; Maarten J Titulaer; Ramani Balu; Susanne Benseler; Christian G Bien; Tania Cellucci; Irene Cortese; Russell C Dale; Jeffrey M Gelfand; Michael Geschwind; Carol A Glaser; Jerome Honnorat; Romana Höftberger; Takahiro Iizuka; Sarosh R Irani; Eric Lancaster; Frank Leypoldt; Harald Prüss; Alexander Rae-Grant; Markus Reindl; Myrna R Rosenfeld; Kevin Rostásy; Albert Saiz; Arun Venkatesan; Angela Vincent; Klaus-Peter Wandinger; Patrick Waters; Josep Dalmau
Journal:  Lancet Neurol       Date:  2016-02-20       Impact factor: 44.182

9.  Overlapping demyelinating syndromes and anti–N-methyl-D-aspartate receptor encephalitis.

Authors:  Maarten J Titulaer; Romana Höftberger; Takahiro Iizuka; Frank Leypoldt; Lindsey McCracken; Tania Cellucci; Leslie A Benson; Huidy Shu; Takashi Irioka; Makito Hirano; Gagandeep Singh; Alvaro Cobo Calvo; Kenichi Kaida; Pamela S Morales; Paul W Wirtz; Tomotaka Yamamoto; Markus Reindl; Myrna R Rosenfeld; Francesc Graus; Albert Saiz; Josep Dalmau
Journal:  Ann Neurol       Date:  2014-03       Impact factor: 10.422

10.  Changes in Serum Ceruloplasmin Levels Based on Immunomodulatory Treatments and Melatonin Supplementation in Multiple Sclerosis Patients.

Authors:  Monika Adamczyk-Sowa; Paweł Sowa; Sebastian Mucha; Jacek Zostawa; Bogdan Mazur; Maciej Owczarek; Krystyna Pierzchała
Journal:  Med Sci Monit       Date:  2016-07-15
  10 in total
  3 in total

1.  Syndrome and outcome of antibody-negative limbic encephalitis.

Authors:  F Graus; D Escudero; L Oleaga; J Bruna; A Villarejo-Galende; J Ballabriga; M I Barceló; F Gilo; S Popkirov; P Stourac; J Dalmau
Journal:  Eur J Neurol       Date:  2018-05-21       Impact factor: 6.089

2.  Optic neuritis as the initial clinical presentation of limbic encephalitis: a case report.

Authors:  Stephanie S L Cheung; Gary K K Lau; Koon-Ho Chan; Ian Y H Wong; Jimmy S M Lai; Wai Kiu Tang; Kendrick C Shih
Journal:  J Med Case Rep       Date:  2018-12-03

3.  Occupation-Associated Fatal Limbic Encephalitis Caused by Variegated Squirrel Bornavirus 1, Germany, 2013.

Authors:  Dennis Tappe; Kore Schlottau; Daniel Cadar; Bernd Hoffmann; Lorenz Balke; Burkhard Bewig; Donata Hoffmann; Philip Eisermann; Helmut Fickenscher; Andi Krumbholz; Helmut Laufs; Monika Huhndorf; Maria Rosenthal; Walter Schulz-Schaeffer; Gabriele Ismer; Sven-Kevin Hotop; Mark Brönstrup; Anthonina Ott; Jonas Schmidt-Chanasit; Martin Beer
Journal:  Emerg Infect Dis       Date:  2018-06       Impact factor: 6.883

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.